CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology
CERVOMED ANNOUNCES NEW DATA AT THE AD/PD™ 2026 SCIENTIFIC CONFERENCE THAT REINFORCE NEFLAMAPIMOD’S POSITIVE EFFECTS IN DEMENTIA WITH LEWY BODIES (DLB) IN PATIENTS WITHOUT ALZHEIMER’S DISEASE CO-PATHOLOGY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.